|
1
|
Jiang R, Xu J, Zhang Y, Zhu X, Liu J and
Tan Y: Ligustrazine alleviate acute lung injury through suppressing
pyroptosis and apoptosis of alveolar macrophages. Front Pharmacol.
12:6805122021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mowery NT, Terzian WTH and Nelson AC:
Acute lung injury. Curr Probl Surg. 57:1007772020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dutta S, Zhu Y, Han Y, Almuntashiri S,
Wang X and Zhang D: Long Noncoding RNA: A novel insight into the
pathogenesis of acute lung injury. J Clin Med. 12:6042023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He YQ, Zhou CC, Yu LY, Wang L, Deng JL,
Tao YL, Zhang F and Chen WS: Natural product derived phytochemicals
in managing acute lung injury by multiple mechanisms. Pharmacol
Res. 163:1052242021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qian J, Chen X, Shu S, Zhang W, Fang B,
Chen X, Zhao Y, Liu Z and Liang G: Design and synthesis novel
di-carbonyl analogs of curcumin (DACs) act as potent
anti-inflammatory agents against LPS-induced acute lung injury
(ALI). Eur J Med Chem. 167:414–425. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan R, Li Y, Han S, Chen X, Chen J, He J,
Gao H and Yang Y, Yang S and Yang Y: Fe-curcumin nanozyme-mediated
reactive oxygen species scavenging and Anti-Inflammation for acute
lung injury. ACS Cent Sci. 8:10–21. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goodman RB, Pugin J, Lee JS and Matthay
MA: Cytokine-mediated inflammation in acute lung injury. Cytokine
Growth Factor Rev. 14:523–535. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnston LK, Rims CR, Gill SE, McGuire JK
and Manicone AM: Pulmonary macrophage subpopulations in the
induction and resolution of acute lung injury. Am J Respir Cell Mol
Biol. 47:417–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong WJ, Yang HH, Guan XX, Xiong JB, Sun
CC, Zhang CY, Luo XQ, Zhang YF, Zhang J, Duan JX, et al: Inhibition
of glycolysis alleviates lipopolysaccharide-induced acute lung
injury in a mouse model. J Cell Physiol. 234:4641–4654. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodriguez-Prados JC, Traves PG, Cuenca J,
Rico D, Aragonés J, Martín-Sanz P, Cascante M and Boscá L:
Substrate fate in activated macrophages: A comparison between
innate, classic, and alternative activation. J Immunol.
185:605–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhong WJ, Liu T, Yang HH, Duan JX, Yang
JT, Guan XX, Xiong JB, Zhang YF, Zhang CY, Zhou Y and Guan CX:
TREM-1 governs NLRP3 inflammasome activation of macrophages by
firing up glycolysis in acute lung injury. Int J Biol Sci.
19:242–257. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roberts DJ and Miyamoto S: Hexokinase II
integrates energy metabolism and cellular protection: Akting on
mitochondria and TORCing to autophagy. Cell Death Differ.
22:248–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeWaal D, Nogueira V, Terry AR, Patra KC,
Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR and Hay N:
Hexokinase-2 depletion inhibits glycolysis and induces oxidative
phosphorylation in hepatocellular carcinoma and sensitizes to
metformin. Nat Commun. 9:4462018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong L, Cui Z, Chen P, Han H, Peng J and
Leng X: Reduced survival of patients with hepatocellular carcinoma
expressing hexokinase II. Med Oncol. 29:909–914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu Y, Cao K, Wang F, Wu W, Mai W, Qiu L,
Luo Y, Ge WP, Sun B, Shi L, et al: Dual roles of hexokinase 2 in
shaping microglial function by gating glycolytic flux and
mitochondrial activity. Nat Metab. 4:1756–1774. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Varghese E, Samuel SM, Líšková A, Samec M,
Kubatka P and Büsselberg D: Targeting glucose metabolism to
overcome resistance to anticancer chemotherapy in breast cancer.
Cancers (Basel). 12:22522020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen CH, Wang BW, Hsiao YC, Wu CY, Cheng
FJ, Hsia TC, Chen CY, Wang Y, Weihua Z, Chou RHT, et al:
PKCdelta-mediated SGLT1 upregulation confers the acquired
resistance of NSCLC to EGFR TKIs. Oncogene. 40:4796–4808. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ros S and Schulze A: Glycolysis back in
the limelight: Systemic targeting of HK2 blocks tumor growth.
Cancer Discov. 3:1105–1107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo D, Tong Y, Jiang X, Meng Y, Jiang H,
Du L, Wu Q, Li S, Luo S, Li M, et al: Aerobic glycolysis promotes
tumor immune evasion by hexokinase2-mediated phosphorylation of
IκBα. Cell Metab. 34:1312–1324.e6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu S and Herschman HR: A tumor agnostic
therapeutic strategy for hexokinase 1-Null/Hexokinase 2-Positive
cancers. Cancer Res. 79:5907–5914. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou QQ, Xiao HT, Yang F, Wang YD, Li P
and Zheng ZG: Advancing targeted protein degradation for metabolic
diseases therapy. Pharmacol Res. 188:1066272023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ho PW, Leung CT, Liu H, Pang SY, Lam CS,
Xian J, Li L, Kung MH, Ramsden DB and Ho SL: Age-dependent
accumulation of oligomeric SNCA/α-synuclein from impaired
degradation in mutant LRRK2 knockin mouse model of Parkinson
disease: Role for therapeutic activation of chaperone-mediated
autophagy (CMA). Autophagy. 16:347–370. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan X, Jin WY, Lu J, Wang J and Wang YT:
Rapid and reversible knockdown of endogenous proteins by
peptide-directed lysosomal degradation. Nat Neurosci. 17:471–480.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang S, Williamson NA and Bogoyevitch MA:
Complementary proteomics strategies capture an ataxin-1 interactome
in Neuro-2a cells. Sci Data. 5:1802622018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie YC, Dong XW, Wu XM, Yan XF and Xie QM:
Inhibitory effects of flavonoids extracted from licorice on
lipopolysaccharide-induced acute pulmonary inflammation in mice.
Int Immunopharmacol. 9:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang L, Lei W, Zhang S and Yao L: MCC950,
a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung
inflammation in mice. Bioorg Med Chem. 30:1159542021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang W, Zheng F, Lin C and Zhang A:
Changes in energy metabolism and macrophage polarization: Potential
mechanisms of arsenic-induced lung injury. Ecotoxicol Environ Saf.
204:1109482020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fosgerau K and Hoffmann T: Peptide
therapeutics: Current status and future directions. Drug Discov
Today. 20:122–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leung RK and Whittaker PA: RNA
interference: From gene silencing to gene-specific therapeutics.
Pharmacol Ther. 107:222–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin X, Ruan X, Anderson MG, McDowell JA,
Kroeger PE, Fesik SW and Shen Y: siRNA-mediated off-target gene
silencing triggered by a 7 nt complementation. Nucleic Acids Res.
33:4527–4535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Castanotto D and Rossi JJ: The promises
and pitfalls of RNA-interference-based therapeutics. Nature.
457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yip BH: Recent advances in CRISPR/Cas9
delivery strategies. Biomolecules. 10:8392020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuscu C, Arslan S, Singh R, Thorpe J and
Adli M: Genome-wide analysis reveals characteristics of off-target
sites bound by the Cas9 endonuclease. Nat Biotechnol. 32:677–683.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen F, Alphonse M and Liu Q: Strategies
for nonviral nanoparticle-based delivery of CRISPR/Cas9
therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol.
12:e16092020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
You L, Tong R, Li M, Liu Y, Xue J and Lu
Y: Advancements and obstacles of CRISPR-Cas9 technology in
translational research. Mol Ther Methods Clin Dev. 13:359–370.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Behr M, Zhou J, Xu B and Zhang H: In vivo
delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta
Pharm Sin B. 11:2150–2171. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou YF, Wang J, Deng MF, Chi B, Wei N,
Chen JG, Liu D, Yin X, Lu Y and Zhu LQ: The Peptide-Directed
lysosomal degradation of CDK5 exerts therapeutic effects against
stroke. Aging Dis. 10:1140–1145. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O'Neill LA and Pearce EJ: Immunometabolism
governs dendritic cell and macrophage function. J Exp Med.
213:15–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Lu B, Sheng L, Zhu Z, Sun H, Zhou Y,
Yang Y, Xue D, Chen W, Tian X, et al: Hexokinase 2-dependent
hyperglycolysis driving microglial activation contributes to
ischemic brain injury. J Neurochem. 144:186–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bao C, Zhu S, Song K and He C: HK2: A
potential regulator of osteoarthritis via glycolytic and
non-glycolytic pathways. Cell Commun Signal. 20:1322022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yuan Y, Fan G, Liu Y, Liu L, Zhang T, Liu
P, Tu Q, Zhang X, Luo S, Yao L, et al: The transcription factor
KLF14 regulates macrophage glycolysis and immune function by
inhibiting HK2 in sepsis. Cell Mol Immunol. 19:504–515. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qian Y, Chen D, Zhu Y, Wu J, Wang Y and
Yang W: Targeting hexokinase 1 alleviates NLRP3-mediated
inflammation in apical periodontitis: A laboratory investigation.
Int Endod J. 56:734–747. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qiao L, Ma J, Zhang Z, Sui W, Zhai C, Xu
D, Wang Z, Lu H, Zhang M, Zhang C, et al: Deficient
Chaperone-Mediated autophagy promotes inflammation and
atherosclerosis. Circ Res. 129:1141–1157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hettwer J, Hinterdobler J, Miritsch B,
Deutsch MA, Li X, Mauersberger C, Moggio A, Braster Q, Gram H,
Robertson AAB, et al: Interleukin-1beta suppression dampens
inflammatory leucocyte production and uptake in atherosclerosis.
Cardiovasc Res. 118:2778–2791. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hill MD, Martin RH, Mikulis D, Wong JH,
Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME,
et al: Safety and efficacy of NA-1 in patients with iatrogenic
stroke after endovascular aneurysm repair (ENACT): A phase 2,
randomised, double-blind, placebo-controlled trial. Lancet Neurol.
11:942–950. 2012. View Article : Google Scholar : PubMed/NCBI
|
